HealthcareResearchers find medical industry funded studies more likely to...

Researchers find medical industry funded studies more likely to find new treatments cost effective

fund manager
Credit: Pixabay/CC0 Public Domain

Medical industry sponsorship of economic evaluations on new treatments are more likely to be found ‘cost-effective’ than independent research across a range of diseases,

Lead author of the study Feng Xie, a McMaster University researcher said that cost-effectiveness analyses (CEAs) are used to set prices and decide if new treatments or devices will be covered by .

New drugs and technologies covered by insurance plans can be much more profitable than those not covered, which may lead to bias in CEAs funded by pharmaceutical or other medical industry firms.

His research team gleaned its data by analyzing the results of more than 8,000 CEAs published between 1976 and March 2021. Nearly 30 percent of these CEAs were sponsored by industry.

“Our provincial and national health-care programs require cost effectiveness analysis for setting new drug or device prices, as well as in support of their coverage policies,” said Xie, a professor of McMaster’s Department of Health Research Methods, Evidence, and Impact.

Xie said this is a critical issue for low or , who often cannot conduct their own CEAs and must instead rely on already published studies that may have industry bias.

“These countries may end up paying more than they are supposed to for new drugs or . Impartial CEAs are especially important for them,” said Xie.

“We must only use those CEAs conducted by independent bodies with full transparency to set the new drug price and support insurance coverage policy. This is important to ensure accessibility and sustainability of our healthcare systems.”

In an editorial published in The BMJ, experts call for improved reporting of results, increased transparency, open-source cost-effectiveness models, and more independent studies, to reduce ‘ reliance on potentially biased CEAs.

Industry sponsorship of CEAs was defined by Xie as an analysis wholly or partially funded by drug, , or .

Eligible CEAs were those that reported an incremental cost-effectiveness ratio using quality-adjusted life years or QALYs, a ‘value for money’ measure of years lived in .

Xie’s findings were published in The BMJ.

Industry-led oncology trials may inflate cost-effectiveness

More information:
Industry sponsorship bias in cost effectiveness analysis: registry based analysis, The BMJ (2022). DOI: 10.1136/bmj-2021-069573

Researchers find medical industry funded studies more likely to find new treatments cost effective (2022, June 22)
retrieved 23 June 2022

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Original Source Link


Please enter your comment!
Please enter your name here

Latest News

An otherwise quiet galaxy in the early universe is spewing star stuff

PASADENA, Calif. — A lucky celestial alignment has given astronomers a rare look at a galaxy in the...

Interest rates and high prices have squeezed out a large number of home buyers, says Harvard’s Hermann

ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via EmailAlexander Hermann, sr. research analyst at...

Polio found in U.K. for the first time in nearly 40 years. Here's what it means

Scientists in Britain have detected multiple versions of the virus in wastewater. Officials say the risk to the...

Jennifer Lopez Kisses Ben Affleck On Set Of His & Matt Damon’s Movie – Hollywood Life

View gallery Jennifer Lopez making an unexpected visit to the set of Ben Affleck and Matt Damon‘s movie seems like a...

Must Read

The WTO is on life support — but the world still needs it

Last week’s marathon ministerial meeting of the World...
- Advertisement -

You might also likeRELATED
Recommended to you